CN1771031A - 用sarms治疗与女性雄激素缺乏(ad if)相关的疾病 - Google Patents

用sarms治疗与女性雄激素缺乏(ad if)相关的疾病 Download PDF

Info

Publication number
CN1771031A
CN1771031A CNA2004800077667A CN200480007766A CN1771031A CN 1771031 A CN1771031 A CN 1771031A CN A2004800077667 A CNA2004800077667 A CN A2004800077667A CN 200480007766 A CN200480007766 A CN 200480007766A CN 1771031 A CN1771031 A CN 1771031A
Authority
CN
China
Prior art keywords
sarm
compound
nhcor
formula
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800077667A
Other languages
English (en)
Chinese (zh)
Inventor
米切尔·S.·斯坦纳
卡伦·A.·韦韦尔卡
杜安·D.·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncternal Therapeutics Inc
Original Assignee
GTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTx Inc filed Critical GTx Inc
Publication of CN1771031A publication Critical patent/CN1771031A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800077667A 2003-01-22 2004-01-20 用sarms治疗与女性雄激素缺乏(ad if)相关的疾病 Pending CN1771031A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44130803P 2003-01-22 2003-01-22
US60/441,308 2003-01-22

Publications (1)

Publication Number Publication Date
CN1771031A true CN1771031A (zh) 2006-05-10

Family

ID=32771915

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800077667A Pending CN1771031A (zh) 2003-01-22 2004-01-20 用sarms治疗与女性雄激素缺乏(ad if)相关的疾病

Country Status (8)

Country Link
US (1) US20050032750A1 (enExample)
EP (1) EP1594490A4 (enExample)
JP (1) JP2006516286A (enExample)
CN (1) CN1771031A (enExample)
AU (1) AU2004206909A1 (enExample)
CA (1) CA2514024A1 (enExample)
TW (1) TW200503729A (enExample)
WO (1) WO2004064747A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103251579A (zh) * 2006-08-24 2013-08-21 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
CN104754939A (zh) * 2012-07-13 2015-07-01 Gtx公司 用选择性雄激素受体调节剂(sarm)治疗雄激素受体(ar)阳性乳癌的方法
WO2025102293A1 (zh) * 2023-11-16 2025-05-22 北京脑科学与类脑研究所 神经活性雄激素受体调节剂及其用途

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US20060019931A1 (en) * 2003-10-14 2006-01-26 Dalton James T Treating bone-related disorders with selective androgen receptor modulators
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
CN1726020A (zh) * 2002-10-16 2006-01-25 Gtx公司 用sarm治疗老年男性雄激素缺乏(adam)相关的疾病
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
CA2626337C (en) 2005-10-19 2015-12-29 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
KR100785038B1 (ko) * 2006-04-17 2007-12-12 삼성전자주식회사 비정질 ＺｎＯ계 ＴＦＴ
ES2780193T3 (es) * 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8791158B2 (en) 2010-01-11 2014-07-29 Gtx, Inc. Methods of treating meibomian gland dysfunction
FR2982261B1 (fr) * 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US12685719B2 (en) 2012-07-13 2026-07-21 University Of Tennessee Research Foundation Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
CA2965372C (en) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CA3002562A1 (en) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CN106405064B (zh) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 一种40岁以上女性骨转换率的评估方法
CN114599369B (zh) 2019-06-03 2026-02-10 哈瓦赫治疗有限公司 用于递送雄激素剂和芳香酶抑制剂的药物制剂和系统以及使用方法
US11701332B2 (en) 2020-11-18 2023-07-18 Bryce Nicholas Day Methods and compositions for treating female sexual interest and arousal disorder
US20230172897A1 (en) * 2021-12-02 2023-06-08 Veru, Inc. Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
EP0635015B1 (en) * 1992-04-10 1997-01-29 Pfizer Inc. Acylaminoindole derivatives as 5-ht1 agonists
US6569896B2 (en) * 2000-08-24 2003-05-27 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
WO2003074449A2 (en) * 2002-02-28 2003-09-12 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
WO2003074473A2 (en) * 2002-02-28 2003-09-12 University Of Tennessee Research Foundation Irreversible selective androgen receptor modulators and methods of use thereof
AU2003241583B2 (en) * 2002-06-17 2009-05-21 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
EP1562594A4 (en) * 2002-10-15 2008-12-17 Univ Tennessee Res Foundation SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH METHYLENE BRIDGES AND METHOD OF USE THEREOF

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103251579A (zh) * 2006-08-24 2013-08-21 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
CN103251579B (zh) * 2006-08-24 2016-12-28 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
CN104754939A (zh) * 2012-07-13 2015-07-01 Gtx公司 用选择性雄激素受体调节剂(sarm)治疗雄激素受体(ar)阳性乳癌的方法
CN108143728A (zh) * 2012-07-13 2018-06-12 Gtx公司 选择性雄激素受体调节剂在治疗乳癌中的用途
CN110840870A (zh) * 2012-07-13 2020-02-28 Gtx公司 选择性雄激素受体调节剂在治疗转移性和难治性乳癌中的应用
WO2025102293A1 (zh) * 2023-11-16 2025-05-22 北京脑科学与类脑研究所 神经活性雄激素受体调节剂及其用途

Also Published As

Publication number Publication date
WO2004064747A3 (en) 2005-01-27
AU2004206909A1 (en) 2004-08-05
JP2006516286A (ja) 2006-06-29
AU2004206909A2 (en) 2004-08-05
EP1594490A2 (en) 2005-11-16
US20050032750A1 (en) 2005-02-10
CA2514024A1 (en) 2004-08-05
WO2004064747A2 (en) 2004-08-05
EP1594490A4 (en) 2006-03-22
TW200503729A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
CN1726034A (zh) 亚甲基桥连的选择性雄激素受体调节剂及其应用方法
CN1726193A (zh) 杂环选择性雄激素受体调节剂及其使用方法
CN1700923A (zh) 多取代的选择性雄激素受体调节剂及其使用方法
CN1694864A (zh) N－桥连选择性雄激素受体调节剂及其使用方法
CN1726019A (zh) 用选择性雄激素受体调节剂治疗肥胖症
CN1726185A (zh) 卤代选择性雄激素受体调节剂及其使用方法
CN1617715A (zh) 用雄激素受体选择性调节剂治疗肌消耗
CN1646115A (zh) 用sarms治疗良性前列腺增生
CN1639110A (zh) 卤代乙酰胺和叠氮化物取代的化合物及其使用方法
US20050032750A1 (en) Treating androgen deficiency in female (ADIF)-associated conditions with SARMS
CN1826313A (zh) 选择性雄激素受体调节剂的大规模合成
CN1646479A (zh) 不可逆选择性雄激素受体调节剂及其使用方法
US6838484B2 (en) Formulations comprising selective androgen receptor modulators
CN1230418C (zh) 选择性雄激素受体调节剂及其使用方法
US7741371B2 (en) Selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) Selective androgen receptor modulators and methods of use thereof
CN1805921A (zh) 选择性雄激素受体调节剂的前药及其使用方法
US8445534B2 (en) Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
CN1671391A (zh) 用于缓解疼痛的新方法及组合物
US20100144871A1 (en) Treating muscle wasting with selective androgen receptor modulators
CN1726020A (zh) 用sarm治疗老年男性雄激素缺乏(adam)相关的疾病
HK1091740A (en) Treating androgen deficiency in female (adif)-associated conditions with sarms
CN1993375A (zh) 具有雄激素作用的甾类前药
CN1835959A (zh) 用选择性雄激素受体调节剂治疗骨相关病症
HK1084375A (en) N-bridged selective androgen receptor modulators and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1091740

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1091740

Country of ref document: HK